Keeping the faith with anticancers
12 March 2010
Peter Charlish
It has been a bad week for anticancer drug development, with two late-stage projects coming to grief and a third being shelved.
First came news that Danish company Genmab’s head and neck cancer product, zalutumumab (HuMax-EGFr), had failed to meet the primary endpoint in its first pivotal Phase...
Please Login to read the full article.
12 March 2010
Peter Charlish
First came news that Danish company Genmab’s head and neck cancer product, zalutumumab (HuMax-EGFr), had failed to meet the primary endpoint in its first pivotal Phase...
Please Login to read the full article.
RELATED CONTENT
EVENTS
09 February 2012
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
